Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 9158572, 6 pages
https://doi.org/10.1155/2017/9158572
Review Article

The Management of Cardiovascular Risk through Epigenetic Biomarkers

1CURS, Laboratoire INSERM U1088, Université de Picardie Jules Verne, chemin du Thil, 80025 Amiens Cedex 1, France
2Interuniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, Viale Europa, 88100 Catanzaro, Italy
3Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Viale Europa, 88100 Catanzaro, Italy

Correspondence should be addressed to Raffaele Serra; ti.zcinu@arresr

Received 21 December 2016; Accepted 15 June 2017; Published 13 July 2017

Academic Editor: Klaus Wimmers

Copyright © 2017 Laurent Metzinger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Abi Khalil, “The emerging role of epigenetics in cardiovascular disease,” Therapeutic Advances in Chronic Disease, vol. 5, no. 4, pp. 178–187, 2014. View at Publisher · View at Google Scholar
  2. A. L. Webster, M. S. Yan, and P. A. Marsden, “Epigenetics and cardiovascular disease,” Canadian Journal of Cardiology, vol. 29, no. 1, pp. 46–57, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Muka, F. Koromani, E. Portilla et al., “The role of epigenetic modifications in cardiovascular disease: A systematic review,” International Journal of Cardiology, vol. 212, pp. 174–183, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. Z. Hai and W. Zuo, “Aberrant DNA methylation in the pathogenesis of atherosclerosis,” Clinica Chimica Acta, vol. 456, pp. 69–74, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. B. J. Toghill, A. Saratzis, S. C. Harrison, A. R. Verissimo, E. B. Mallon, and M. J. Bown, “The potential role of DNA methylation in the pathogenesis of abdominal aortic aneurysm,” Atherosclerosis, vol. 241, no. 1, pp. 121–129, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Fernández-Sanlés, S. Sayols-Baixeras, I. Subirana, I. R. Degano, and R. Elosua, “Association between DNA methylation and coronary heart disease or other atherosclerotic events: a systematic review,” Atherosclerosis, 2017. View at Publisher · View at Google Scholar
  7. S. Raghuraman, I. Donkin, S. Versteyhe, R. Barrès, and D. Simar, “The emerging role of epigenetics in inflammation and immunometabolism,” Trends in Endocrinology & Metabolism, vol. 27, no. 11, pp. 782–795, 2016. View at Publisher · View at Google Scholar
  8. M.-F. Seronde, M. Vausort, E. Gayat et al., “Circulating microRNAs and outcome in patients with acute heart failure,” PLoS ONE, vol. 10, no. 11, Article ID e0142237, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Karakas, C. Schulte, S. Appelbaum et al., “Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study,” European Heart Journal, vol. 38, no. 7, pp. 516–523, 2017. View at Publisher · View at Google Scholar
  10. K. Simpson, A. Wonnacott, D. J. Fraser, and T. Bowen, “MicroRNAs in diabetic nephropathy: from biomarkers to therapy,” Current Diabetes Reports, vol. 16, no. 3, article 35, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Metzinger-Le Meuth, S. Burtey, P. Maitrias, Z. A. Massy, and L. Metzinger, “MicroRNAs in the pathophysiology of CKD-MBD: biomarkers and innovative drugs,” Biochimica et Biophysica Acta, vol. 1863, no. 1, pp. 337–345, 2017. View at Publisher · View at Google Scholar
  12. E. M'Baya-Moutoula, L. Louvet, V. Metzinger-Le Meuth, Z. A. Massy, and L. Metzinger, “High inorganic phosphate concentration inhibits osteoclastogenesis by modulating miR-223,” Biochimica et Biophysica Acta, vol. 1852, no. 10, pp. 2202–2212, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Taïbi, V. Metzinger-Le Meuth, E. M'Baya-Moutoula et al., “Possible involvement of microRNAs in vascular damage in experimental chronic kidney disease,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1842, no. 1, pp. 88–98, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Mondadori dos Santos, L. Metzinger, O. Haddad et al., “MiR-126 is involved in vascular remodeling under laminar shear stress,” BioMed Research International, vol. 2015, Article ID 497280, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. K. Gupta, A. Foinquinos, S. Thum et al., “Preclinical development of a microRNA-based therapy for elderly patients with myocardial infarction,” Journal of the American College of Cardiology, vol. 68, no. 14, pp. 1557–1571, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Piegari, R. Russo, D. Cappetta et al., “MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat,” Oncotarget, vol. 7, no. 38, pp. 62312–62326, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Sawada, M. Kon, S. Wada, T. Ushida, K. Suzuki, and T. Akimoto, “Profiling of circulating microRNAs after a bout of acute resistance exercise in humans,” PLoS ONE, vol. 8, no. 7, Article ID e70823, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. A. H. Van Craenenbroeck, K. J. Ledeganck, K. Van Ackeren et al., “Plasma levels of microRNA in chronic kidney disease: Patterns in acute and chronic exercise,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 309, no. 12, pp. H2008–H2016, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Nielsen, C. Scheele, C. Yfanti et al., “Muscle specific microRNAs are regulated by endurance exercise in human skeletal muscle,” Journal of Physiology, vol. 588, part 20, pp. 4029–4037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Mueller, F. A. Breil, G. Lurman et al., “Different molecular and structural adaptations with eccentric and conventional strength training in elderly men and women,” Gerontology, vol. 57, no. 6, pp. 528–538, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. O. El-Maarri, M. Walier, F. Behne et al., “Methylation at global LINE-1 repeats in human blood are affected by gender but not by age or natural hormone cycles,” PLoS ONE, vol. 6, no. 1, Article ID e16252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Wei, S. Liu, Z. Su, R. Cheng, X. Bai, and X. Li, “LINE-1 hypomethylation is associated with the risk of coronary heart disease in Chinese population,” Arquivos Brasileiros de Cardiologia, vol. 102, no. 5, pp. 481–487, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. R.-T. Lin, E. Hsi, H.-F. Lin, Y.-C. Liao, Y.-S. Wang, and S.-H. H. Juo, “LINE-1 methylation is associated with an increased risk of ischemic stroke in men,” Current Neurovascular Research, vol. 11, no. 1, pp. 4–9, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Rask-Andersen, D. Martinsson, M. Ahsan et al., “Epigenome-wide association study reveals differential DNA methylation in individuals with a history of myocardial infarction,” Human Molecular Genetics, vol. 25, pp. 4739–4748, 2016. View at Google Scholar
  25. C. Gallego-Fabrega, C. Carrera, J.-L. Reny et al., “PPM1A methylation is associated with vascular recurrence in aspirin-treated patients,” Stroke, vol. 47, no. 7, pp. 1926–1929, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Gallego-Fabrega, C. Carrera, J. L. Reny et al., “TRAF3 epigenetic regulation is associated with vascular recurrence in patients with ischemic stroke,” Stroke, vol. 47, no. 5, pp. 1180–1186, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Pandya, T. Kohro, I. Mimura et al., “Distribution of histone3 lysine 4 trimethylation at T3-responsive loci in the heart during reversible changes in gene expression,” Gene Expression, vol. 15, no. 4, pp. 183–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Yang, W. Xu, and S. Hu, “Heart failure: advanced development in genetics and epigenetics,” BioMed Research International, vol. 2015, Article ID 352734, 11 pages, 2015. View at Publisher · View at Google Scholar
  29. L. X. Zhang, M. DeNicola, X. Qin et al., “Specific inhibition of HDAC4 in cardiac progenitor cells enhances myocardial repairs,” American Journal of Physiology—Cell Physiology, vol. 307, no. 4, pp. C358–C372, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. W. E. Ek, A. K. Hedman, S. Enroth et al., “Genome-wide DNA methylation study identifies genes associated with the cardiovascular biomarker GDF-15,” Human Molecular Genetics, vol. 25, no. 4, pp. 817–827, 2016. View at Publisher · View at Google Scholar
  31. D. P. Bartel, “MicroRNAs: target recognition and regulatory functions,” Cell, vol. 136, no. 2, pp. 215–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. de Franciscis, L. Metzinger, and R. Serra, “The discovery of novel genomic, transcriptomic, and proteomic biomarkers in cardiovascular and peripheral vascular disease: the state of the art,” BioMed Research International, vol. 2016, Article ID 7829174, 10 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Taïbi, V. Metzinger-Le Meuth, Z. A. Massy, and L. Metzinger, “MiR-223: an inflammatory oncomiR enters the cardiovascular field,” Biochimica et Biophysica Acta, vol. 1842, no. 7, pp. 1001–1009, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Londin, P. Loher, A. G. Telonis et al., “Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 10, pp. E1106–E1115, 2015. View at Publisher · View at Google Scholar
  35. H. Guo, N. T. Ingolia, J. S. Weissman, and D. P. Bartel, “Mammalian microRNAs predominantly act to decrease target mRNA levels,” Nature, vol. 466, no. 7308, pp. 835–840, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H. J. Curtis, C. R. Sibley, and M. J. A. Wood, “Mirtrons, an emerging class of atypical miRNA,” Wiley Interdisciplinary Reviews: RNA, vol. 3, no. 5, pp. 617–632, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Maitrias, V. Metzinger-Le Meuth, Z. A. Massy et al., “MicroRNA deregulation in symptomatic carotid plaque,” Journal of Vascular Surgery, vol. 62, no. 5, pp. 1245–1250.e1, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., “Circulating microRNAs as stable blood-based markers for cancer detection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513–10518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. M. P. Hunter, N. Ismail, X. Zhang et al., “Detection of microRNA expression in human peripheral blood microvesicles,” PLoS ONE, vol. 3, no. 11, Article ID e3694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Menéndez, P. Villarejo, D. Padilla, J. M. Menéndez, and J. A. R. Montes, “Diagnostic and prognostic significance of serum microRNAs in colorectal cancer,” Journal of Surgical Oncology, vol. 107, no. 2, pp. 217–220, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. T. C. Roberts, A. M. L. Coenen-Stass, and M. J. A. Wood, “Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine Serum,” PLoS ONE, vol. 9, no. 2, Article ID e89237, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Schwarzenbach, N. Nishida, G. A. Calin, and K. Pantel, “Clinical relevance of circulating cell-free microRNAs in cancer,” Nature Reviews Clinical Oncology, vol. 11, no. 3, pp. 145–156, 2014. View at Publisher · View at Google Scholar
  43. S. Fichtlscherer, A. M. Zeiher, and S. Dimmeler, “Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 11, pp. 2383–2390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. L. N. Masi, T. D. A. Serdan, A. C. Levada-Pires et al., “Regulation of gene expression by exercise-related micrornas,” Cellular Physiology and Biochemistry, vol. 39, no. 6, pp. 2381–2397, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Uchida and S. Dimmeler, “Long noncoding RNAs in cardiovascular diseases,” Circulation Research, vol. 116, no. 4, pp. 737–750, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Kumarswamy, C. Bauters, I. Volkmann et al., “Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure,” Circulation Research, vol. 114, no. 10, pp. 1569–1575, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Yan, B. Zhang, N. Liu et al., “Circulating long noncoding RNA UCA1 as a novel biomarker of acute myocardial infarction,” BioMed Research International, vol. 2016, Article ID 8079372, 7 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  48. R. F. J. Kwekkeboom, Z. Lei, P. A. Doevendans, R. J. P. Musters, and J. P. G. Sluijter, “Targeted delivery of miRNA therapeutics for cardiovascular diseases: Opportunities and challenges,” Clinical Science, vol. 127, no. 6, pp. 351–365, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. H. L. A. Janssen, H. W. Reesink, E. J. Lawitz et al., “Treatment of HCV infection by targeting microRNA,” The New England Journal of Medicine, vol. 368, no. 18, pp. 1685–1694, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. L. Hao, P. C. Patel, A. H. Alhasan, D. A. Giljohann, and C. A. Mirkin, “Nucleic acid-gold nanoparticle conjugates as mimics of microRNA,” Small, vol. 7, no. 22, pp. 3158–3162, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. F. M. Kouri, L. A. Hurley, W. L. Daniel et al., “MiR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma,” Genes and Development, vol. 29, no. 7, pp. 732–745, 2015. View at Publisher · View at Google Scholar · View at Scopus